Fluicell AB (FLUI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Fluicell AB (FLUI) has a cash flow conversion efficiency ratio of 0.017x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr248.00K ≈ $26.69K USD) by net assets (Skr14.21 Million ≈ $1.53 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Fluicell AB stock valuation for the company's overall valuation and market capitalisation.
Fluicell AB - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Fluicell AB's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Fluicell AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Fluicell AB ranked by their cash flow conversion efficiency. Explore FLUI cash flow quality score to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Nicoccino Holding AB
ST:NICO
|
-0.936x |
|
NedSense Enterprises NV
AS:NEDSE
|
0.067x |
|
C&C Group plc
LSE:CCR
|
0.072x |
|
Austin Metals Ltd
AU:AYT
|
-0.023x |
|
Nandani Creation Limited
NSE:JAIPURKURT
|
-0.166x |
|
Belmont Resources Inc
V:BEA
|
-0.038x |
|
CCH Holdings Ltd Ordinary Shares
NASDAQ:CCHH
|
N/A |
|
Ambica Agarbathies & Aroma industries Limited
NSE:AMBICAAGAR
|
0.071x |
Annual Cash Flow Conversion Efficiency for Fluicell AB (2016–2025)
The table below shows the annual cash flow conversion efficiency of Fluicell AB from 2016 to 2025. View FLUI live share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr10.90 Million ≈ $1.17 Million |
Skr-4.95 Million ≈ $-532.16K |
-0.454x | +44.32% |
| 2024-12-31 | Skr19.23 Million ≈ $2.07 Million |
Skr-15.67 Million ≈ $-1.69 Million |
-0.815x | +98.73% |
| 2023-12-31 | Skr425.00K ≈ $45.74K |
Skr-27.23 Million ≈ $-2.93 Million |
-64.064x | -7037.92% |
| 2022-12-31 | Skr23.45 Million ≈ $2.52 Million |
Skr-21.04 Million ≈ $-2.26 Million |
-0.898x | +7.98% |
| 2021-12-31 | Skr19.11 Million ≈ $2.06 Million |
Skr-18.64 Million ≈ $-2.01 Million |
-0.975x | -8.24% |
| 2020-12-31 | Skr19.50 Million ≈ $2.10 Million |
Skr-17.57 Million ≈ $-1.89 Million |
-0.901x | +46.02% |
| 2019-12-31 | Skr10.22 Million ≈ $1.10 Million |
Skr-17.07 Million ≈ $-1.84 Million |
-1.669x | -213.09% |
| 2018-12-31 | Skr23.37 Million ≈ $2.52 Million |
Skr-12.46 Million ≈ $-1.34 Million |
-0.533x | +34.76% |
| 2017-12-31 | Skr9.58 Million ≈ $1.03 Million |
Skr-7.83 Million ≈ $-842.74K |
-0.817x | +72.63% |
| 2016-12-31 | Skr1.84 Million ≈ $198.12K |
Skr-5.50 Million ≈ $-591.56K |
-2.986x | -- |
About Fluicell AB
Fluicell AB (publ), a life science company, develops and provides clay instruments for 3D bioprinting and cell analysis and flow control on single-cell level in Sweden. The company offers BIOPEN, a powerful tool for high precision cell biology that uses open volume microfluidics; Biozone 6 that generate dose-response curves or study the effects of multiple drug compounds; and Dynaflow Resolve sys… Read more